

**MEETING OF THE NATIONAL COMPETENT AUTHORITIES ON PRICING AND  
REIMBURSEMENT AND PUBLIC HEALTHCARE PAYERS (NCAPR)**

**30 MARCH 2023, 9H00-16H45 CET**

**WORLD TRADE CENTER, KUNGSBRON 1, STOCKHOLM, SWEDEN (PHYSICAL)**

**DRAFT AGENDA**

**8.30 – 9.00**    *Registration and coffee*

**9.00 – 9.30**    **Opening by the co-chairs: stepping up the affordability agenda**

- *Swedish Presidency – Agneta Karlsson, Director General, TLV; Fredrik Andersson, Head of Department for Analyses, Market and Dental Care, TLV*
- *European Commission – Sylvain Giraud, Head of Unit D2 (Medical Products: Quality, Safety, Innovation), DG SANTE*

**Adoption of the meeting notes from the last NCAPR Plenary**

**9.30 – 10.30** **Debrief of NCAPR stakeholder event: “New legislative landscape for pharmaceuticals in the EU: How do we prepare?”**

*The discussions from the stakeholder event organised by the Swedish Presidency the previous day should give food for thought. In small groups the NCAPR will reflect on what this means for the national and European level, in light of upcoming legislative changes.*

- *Reflections on the input from the stakeholder event*
- *Small group discussions*
- *Sharing of outcomes in plenary*

**10.30 – 12.45** **Willingness and ability to pay: What should we as payers (or buyers) be willing to pay for?**

*The willingness and ability to pay differs between the member states but it is not only income level that drives this. What should we as payers (or buyers) be willing to pay for? And what does our political level think of this?*

- *Cost-aspects of Orphan legislation and microeconomic calculations - Douglas Lundin, Chief Economist, TLV and Sofie Alverlind, Pharmacist and Project Leader, TLV.*
- *What are the limits of willingness to pay? The system’s limitations – Yannis Natsis, Director European Social Insurance Platform*
- *RWD and new expensive pharmaceuticals – Anders Viberg, Senior Analyst TLV*

**11.00 – 11.30**

<<Coffee break>>

- *Orphan medicinal products: What we are surely wishing to pay for this effect, not the orphan status as such. How should we handle issues like uncertainties? – Anja Schiel, Senior Advisor Norwegian Medicines Agency*
- *Experiences of a medicinal product outside our willingness to pay – Kim Helleberg Madsen, Director of the Division for Pharmacoeconomics and Availability of Medicines, Danish Medicines Agency*
- *French Budget Cap system – Emilie Sam, Head of the Medicines sector at the General Secretary of the Economic Committee for healthcare products (CEPS)*
- *Discussion*

12.45 – 14.00

<<Lunch>>

#### **14.00 – 14.50 Impact of inflation in pricing, reimbursement and follow-up decisions**

*For the first time in more than a decade inflation has become a real factor in society. It also affects the situation for pricing of pharmaceuticals when companies try to pass on their costs to the consumers. This is particularly noticeable for older drugs where the companies hesitate to keep them on the market.*

- *Impact of inflation on reimbursement and follow-up decisions - Per Troein, IQVIA*
- *Q&A to Per Troein's presentation*
- *Impact of inflation on the generics market, practical case*
- *How to deal with increasing expenditure and simultaneously implement measures to avoid price decreases that may lead to shortages? Sónia Caldeira, INFARMED, Portugal*
- *Dealing with the impact of inflation on prices of medicines. A case from Spain. Estibaliz Espinosa, Spanish Ministry of Health*
- *Dutch Experiences of the current situation, Aldo Golja, Strategic Advisor on Pricing and Reimbursement, Dutch Ministry of Health (to be confirmed)*
- *Discussion*

14.50 – 15.20

<<Coffee break>>

#### **15.20 – 16.30 What can be done to increase competition, also among patented drugs?**

*We know that competition between similar products drive prices down. How can this be enhanced either in the revised legislation or in measures made by the NCAPR-members themselves?*

- *Overview of the OECD Health Working Paper on “enhancing on-patent competition” – Ruth Lopert, Senior Health Economist and Policy Analyst, OECD*

- *Lessons learned from competition cases – Paul Csiszar, Director of Basic Industries, Manufacturing and Agriculture at DG Competition, European Commission*
- *Competition drives lower prices. Exhibits from MS on competition creating measures*
  - *Erik Saghdal, Temp. Head of Procurement for the Pharmaceuticals Division, Norwegian Hospital Procurement Trust*
  - *Robert Sauermann, Deputy Head of Pharmaceutical Affairs, Austrian Social Insurance (DVSV)*
  - *Nemeth Gergely, Project Manager National Health Insurance Fund (NEAK)*
- *How can Horizon Scanning and IHSI be used to promote competition? – Kim Helleberg Madsen, Director of the Division for Pharmacoeconomics and Availability of Medicines, Danish Medicines Agency*
- *Discussion*

### **16.30 – 16.35 Information points**

### **16.35 – 16.45 Conclusions/ Next meeting**

\* Note: The NCAPR members are also invited by the Swedish Presidency to a Stakeholder event that takes place on the 29<sup>th</sup> of March 2023.

\* \* \* \* \*